US FDA confirms reinvestigation of alleged misconduct by agency staff
This article was originally published in RAJ Devices
The US Food and Drug Administration has confirmed that the Office of Inspector General at the Department of Health and Human Services is re-opening a controversial investigation into the alleged misconduct of senior managers at the agency's Center for Devices and Radiological Health1.
You may also be interested in...
An independent audit of the new EU Clinical Trials Information System has finally commenced, indicating that plans are on track for the EU Clinical Trial Regulation to be implemented from December 2021.
EU regulators have agreed on supplementary pharmacovigilance requirements applicable to COVID-19 vaccines following approval.
The UK Medicines and Healthcare products Regulatory Agency wants clinical trial sponsors to integrate available regulatory flexibilities into normal practice so that their studies can withstand further potential disruptions from the COVID-19 pandemic.